Fruquintinib (Elunate) has been included in the latest update of the China National Reimbursement Drug List (NRDL). NRDL inclusion will broaden fruquintinib’s availability and accelerate patient access across China. From January 1, 2020, fruquintinib will automatically be available in all staterun hospital pharmacies in China, and patients covered by NHSA (National Healthcare Security Administration) insurance schemes will be reimbursed. Fruquintinib was approved in third-line colorectal cancer (3L CRC) in China in September 2018 and launched in November 2018 by Chi-Med’s partner Eli Lilly. From launch to end-July 2019, the drug generated $8.3m in royalty/ manufacturing revenue for Chi-Med on c$13.1m of in-market China sales.
29 Nov 2019
Elunate (fruquintinib) secures China NRDL listing
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Elunate (fruquintinib) secures China NRDL listing
HUTCHMED (China) Limited (HCM:LON) | 267 -2.7 (-0.4%) | Mkt Cap: 2,326m
- Published:
29 Nov 2019 -
Author:
Franc Gregori -
Pages:
2
Fruquintinib (Elunate) has been included in the latest update of the China National Reimbursement Drug List (NRDL). NRDL inclusion will broaden fruquintinib’s availability and accelerate patient access across China. From January 1, 2020, fruquintinib will automatically be available in all staterun hospital pharmacies in China, and patients covered by NHSA (National Healthcare Security Administration) insurance schemes will be reimbursed. Fruquintinib was approved in third-line colorectal cancer (3L CRC) in China in September 2018 and launched in November 2018 by Chi-Med’s partner Eli Lilly. From launch to end-July 2019, the drug generated $8.3m in royalty/ manufacturing revenue for Chi-Med on c$13.1m of in-market China sales.